Patient Advocacy: A Strategic Partner in Rare Disease Commercialisation

sharonshieldsconsu

Aug 22

5 min read

Rare Disease as a Strategic Growth Engine

Rare disease is no longer just a scientific or regulatory story — it is a commercial one. But in rare disease, “the market” is not an abstract concept. It is a small, tightly connected ecosystem of patients, caregivers, advocates, clinicians, and payers who all know each other — and who expect to be true partners.

Speaking to many global commercial leader over the last few weeks Patient advocacy has been a re-occurring theme.

For global commercial leaders and asset leads, that changes the rules. Patient advocacy is not a “nice to have” or a late-stage communications activity. It is one of the central levers that determines whether a rare-disease asset reaches patients, sustains value, and maintains trust over time.

WHY PATIENT ADVOCACY MATTERS IN RARE DISEASE

In mainstream therapeutic areas, companies can succeed with broad promotion, large salesforces, and payer contracting. In rare disease, those levers are weaker. Instead, commercial success is heavily influenced by:

How quickly undiagnosed patients are found
How effectively care is coordinated across fragmented systems
How payers perceive the “real” burden of disease and unmet need
How much trust exists between the community and the sponsor

Patient-advocacy organisations sit at the centre of all four.

They are often the first touchpoint for newly diagnosed families, the primary source of practical disease information, and the conveners of specialist centres and key opinion leaders. They shape the narrative on benefit–risk, access, and appropriate use in ways that traditional promotion simply cannot.

For commercial leaders, this makes advocacy strategy a core component of the rare-disease operating model — not an adjunct.

WHAT PATIENT ADVOCACY LOOKS LIKE IN PRACTICE

In rare disease, “patient advocacy” spans several layers:

Patient and caregiver support – helplines, peer groups, education materials, navigation through diagnosis and treatment
Community-building – registries, conferences, online communities that connect small, geographically dispersed populations
Evidence generation – natural-history studies, burden-of-illness surveys, preference studies, and PRO development
Policy and access – lobbying for newborn screening, reimbursement, and coverage policies; engaging HTA bodies and payers
Research partnerships – input into trial design, feasibility, endpoints, and acceptable risk–benefit trade-offs

Each of these activities directly affects traditional commercial metrics: time to diagnosis, time to treatment, adherence, persistence, and payer acceptance.

THE COMMERCIAL UPSIDE OF STRONG ADVOCACY PARTNERSHIPS

Done well, early and authentic advocacy engagement creates tangible advantages:

1. Faster and more accurate patient identification

Advocacy groups are often the only entities with a comprehensive view of the patient community in a given country.

Strategic benefit:

Shorter time to diagnosis through co-developed disease-awareness campaigns and symptom checklists
More efficient patient-finding by linking advocacy registries, specialist centres, and your own patient-support programs
Higher referral quality because educational materials are trusted and co-branded with recognised community leaders

2. Better-aligned trial design and higher recruitment success

In ultra-rare conditions, recruitment is a fundamental risk. Advocates can help:

Shape inclusion/exclusion criteria that reflect real-world patient profiles
Prioritise endpoints and PROs that matter to families and to HTA bodies
Reduce recruitment friction by building trust and clarifying expectations

Commercially, this means fewer protocol amendments, faster recruitment, and evidence packages that resonate with payers and clinicians.

3. Stronger access and pricing narratives

Payers increasingly look beyond clinical endpoints to understand the lived burden of disease.

Advocacy organisations can:

Provide structured data on quality of life, caregiver burden, and indirect costs
Co-create value stories that reflect what “meaningful benefit” actually looks like
Support HTA submissions with independent, patient-voice evidence

This does not replace robust clinical evidence. But it strengthens your ability to defend premium pricing in small, high-need populations and sustain value over time.

4. Durable trust and brand preference

In small communities, reputation is cumulative and long-lived. How you interact with advocacy groups before, during, and after launch shapes:

Willingness to participate in future trials
Openness to new indications or next-generation therapies
Community response when safety signals or supply issues arise

Sponsors perceived as long-term partners — not opportunistic entrants — enjoy higher resilience when challenges appear.

BUILDING ADVOCACY INTO YOUR OPERATING MODEL

To capture this value, advocacy engagement must be intentional, resourced, and compliant. Four design questions for commercial and asset leads:

1. When do you engage?

In rare disease, “late” is effectively “never.” Effective companies:

Map the advocacy landscape at target identification / preclinical stages
Engage before protocol finalisation to incorporate patient input
Maintain continuity from early development through launch and lifecycle management

Waiting until Phase III or pre-launch turns advocacy into a transactional activity and limits strategic impact.

2. Who owns the relationship?

Ownership cannot sit solely in communications or a single country team.

Leading organisations:

Establish cross-functional governance for advocacy (medical, commercial, access, clinical operations, and legal/compliance)
Define clear principles for engagement: transparency, non-promotion, data use, and conflict-of-interest management
Designate global and regional advocacy leads to ensure consistency while allowing local adaptation

3. How do you create mutual value?

Advocacy organisations are typically resource-constrained. Partnerships work best when they address shared priorities:

Co-develop disease-education campaigns and materials that are non-promotional, disease focused, and evidence based
Fund or support natural-history registries, burden-of-illness studies, or patient-preference research with clear data-governance frameworks
Invest in capacity-building (e.g., training on HTA processes, data interpretation, or policy engagement)

The goal is not to “buy influence” but to build infrastructure that benefits the entire community — including future competitors.

4. How do you manage risk?

Regulation around industry–patient-organisation interactions is tightening.

To stay on the right side of trust and compliance:

Use formal agreements that define scope, funding, data ownership, and publication rights
Maintain clear separation between promotional activities and advocacy support
Document decision-making around which groups you support and why
Ensure medical and compliance sign-off on all co-created materials

In rare disease, one misstep can damage relationships across the entire global community.

WHAT “GOOD” LOOKS LIKE FOR COMMERCIAL LEADERS

For global commercial leaders and asset leads, integrating advocacy means:

Strategy
- Advocacy mapping is part of early market landscaping and forecasts
- Patient-voice insights inform segmentation, positioning, and value propositions
Execution
- Launch plans include co-created disease-education and patient-finding initiatives
- Patient-support programs are designed with direct input from advocacy groups
Measurement
- KPIs go beyond “number of meetings” to track impact on:
  - Time to diagnosis
  - Trial feasibility and recruitment timelines
  - Access decisions and payer feedback
  - Adherence, persistence, and real-world outcome

Culture
- Teams are trained to see advocacy groups as strategic partners, not just stakeholders to be “managed”
- Incentives reward long-term relationship building and community impact, not only short-term uptake

FROM “PATIENT CENTRICITY” TO PATIENT PARTNERSHIP

Many organisations talk about “patient centricity.” In rare disease, that language is no longer sufficient. The expectation — from regulators, payers, and communities — is for genuine partnership.

Advocacy organisations:

Inform regulatory guidance and health-technology assessments
Influence clinical-practice guidelines and referral pathways
Shape public and political opinion on what constitutes acceptable risk, cost, and access

For companies building the next generation of rare-disease assets, this is a strategic reality. Advocacy engagement, done well, enhances scientific credibility, accelerates access, and creates durable commercial value. Done poorly, or too late, it can slow trials, weaken access, and erode trust.

Rare disease is where scientific innovation, regulatory evolution, and patient advocacy are converging fastest. For commercial leaders, building structured, transparent, and long-term partnerships with patient advocates is no longer optional. It is a core capability — one that will increasingly differentiate the companies that lead in rare disease from those that merely participate.

For executive search, this means explicitly assessing track record in patient and advocacy engagement, not treating it as a “nice to have.” For talent leadership, it means developing and rewarding these skills internally so that advocacy partnership becomes part of the organisation’s leadership DNA.

REFERENCES

[1] U.S. Food and Drug Administration. Accelerating Rare Disease Cures (ARC) Program and Rare Disease Endpoint Advancement (RDEA) initiatives.

[2] IQVIA. “Rare Diseases: Navigating the Complex Landscape.” Industry commentary and best-practice analyses.